Hot Features
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-1... Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.0001 | 0.0001 | 1.0E-6 | 1990 | 9.565E-5 | CS |
| 4 | 0 | 0 | 0.0001 | 0.20005 | 1.0E-6 | 3352 | 9.92E-5 | CS |
| 12 | 0 | 0 | 0.0001 | 0.20005 | 1.0E-6 | 2962 | 0.00011473 | CS |
| 26 | 0 | 0 | 0.0001 | 0.20005 | 1.0E-6 | 2442 | 0.00010868 | CS |
| 52 | 9.9E-5 | 9900 | 1.0E-6 | 0.35 | 1.0E-6 | 20178 | 0.00039136 | CS |
| 156 | 9.9E-5 | 9900 | 1.0E-6 | 0.35 | 1.0E-6 | 10014 | 0.00033826 | CS |
| 260 | -0.0018 | -94.7368421053 | 0.0019 | 0.35 | 1.0E-6 | 81049 | 0.06053324 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.